Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging SARS-CoV-2 Resistance After Antiviral Treatment.

JAMA network open - 3 Sept 2024

Tamura Trevor J, Choudhary Manish C, Deo Rinki, Yousuf Fizah, Gomez Anadela Navarrete, Edelstein Gregory E, Boucau Julie, Glover Owen T, Barry Mamadou, Gilbert Rebecca F, Reynolds Zahra, Li Yijia, Tien Dessie, Vyas Tammy D, Passell Eliza, Su Karry, Drapkin Sarah, Abar Emory G, Kawano Yumeko, Sparks Jeffrey A, Wallace Zachary S, Vyas Jatin M, Shafer Robert W, Siedner Mark J, Barczak Amy K, Lemieux Jacob E, Li Jonathan Z

Abstract excerpt

Importance: Previous studies have identified mutations in SARS-CoV-2 strains that confer resistance to nirmatrelvir, yet how often this resistance arises and its association with posttreatment virologic rebound is not well understood. Objective: To examine the prevalence of emergent antiviral resistance after nirmatrelvir treatment and its association with virologic rebound. Design, Setting, and Participants:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to Adenosine Monophosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Cohort Studies

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to Drug Resistance, Viral

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 39320890
DOI: 10.1001/jamanetworkopen.2024.35431
PMCID: PMC11425144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging SARS-CoV-2 Resistance After Antiviral Treatment.PMID 39320890Read ↗

Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in VitroSemantic proximity Read ↗

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).Semantic proximity Read ↗

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or MutationsSemantic proximity Read ↗

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)Semantic proximity Read ↗

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsSemantic proximity Read ↗

Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1Semantic proximity Read ↗

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug ResistanceSemantic proximity Read ↗

Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.Semantic proximity Read ↗

Evolution of Antiviral Drug Resistance in SARS-CoV-2Semantic proximity Read ↗

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.Semantic proximity Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.